DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Kentucky Retirement Systems Insurance Trust Fund

Kentucky Retirement Systems Insurance Trust Fund lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 7.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,864 shares of the medical device company’s stock after selling 963 shares during the period. Kentucky Retirement Systems Insurance Trust Fund’s holdings in DexCom were worth $795,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of DexCom in the second quarter valued at approximately $25,000. Sachetta LLC increased its position in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the period. Crewe Advisors LLC bought a new stake in DexCom during the 1st quarter valued at $29,000. Riverview Trust Co boosted its position in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the period. Finally, DT Investment Partners LLC grew its stake in shares of DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DXCM shares. Barclays reduced their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. JPMorgan Chase & Co. increased their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 price objective on shares of DexCom in a research note on Tuesday, July 23rd. Sanford C. Bernstein upped their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Finally, Morgan Stanley lowered their price target on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $104.59.

Insider Activity

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of DXCM opened at $75.88 on Monday. The business’s 50-day moving average is $70.03 and its 200-day moving average is $91.42. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a market capitalization of $29.64 billion, a price-to-earnings ratio of 45.44, a P/E/G ratio of 2.33 and a beta of 1.17. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.